Chow James C H, Au Kwok Hung, Mang Oscar W K, Cheung Ka Man, Ngan Roger K C
Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong.
Hong Kong Cancer Registry, Hong Kong.
Asia Pac J Clin Oncol. 2019 Feb;15(1):48-55. doi: 10.1111/ajco.12994. Epub 2018 Jun 22.
Second primary tumor (SPT) is a serious late complication after definitive radiotherapy for nasopharyngeal carcinoma (NPC). We evaluated the incidence, pattern, risk factors and survival impact of SPT in NPC patients following definitive intensity-modulated radiotherapy (IMRT).
A retrospective review of 780 consecutive IMRT-treated NPC patients between February 2003 and September 2011 was conducted. Cumulative SPT incidence and overall survival after SPT diagnosis were estimated. Associations between clinical characteristics and SPT risk were analyzed. Standardized incidence ratios (SIR) were calculated using age, gender and calendar-year-specific cancer incidences from the Hong Kong Cancer Registry.
At a median follow-up of 7.5 years, 51 SPTs (6.7%) were identified, 22 (43.1%) of which occurred within previous radiotherapy fields. Tongue cancers (31.8%) and sarcomas of the head and neck (31.8%) were the most common in-field SPTs. Age [hazard ratio (HR), 1.051; 95% confidence interval (CI), 1.025-1.078] and smoking status (HR, 1.755; 95% CI, 1.002-3.075) were independent risk factors associated with SPT development. Median overall survival after SPT diagnosis was 2.9 years. There was an 84% increase in cancer risk (SIR, 1.84; 95% CI, 1.37-2.42) compared with the general population. Significant excess risks were observed for sarcoma, tongue, oropharyngeal, prostate and liver cancer. Excess risks were higher beyond 5 years of follow-up.
Substantial risk of SPT, especially for in-field sarcoma and tongue cancers, exists after definitive IMRT for NPC. SPT severely negates longevity of NPC survivors. High awareness and careful surveillance is warranted for this late lethal complication.
第二原发性肿瘤(SPT)是鼻咽癌(NPC)根治性放疗后一种严重的晚期并发症。我们评估了接受根治性调强放疗(IMRT)的NPC患者中SPT的发生率、模式、危险因素及对生存的影响。
对2003年2月至2011年9月期间连续接受IMRT治疗的780例NPC患者进行回顾性分析。估计累积SPT发生率及SPT诊断后的总生存率。分析临床特征与SPT风险之间的关联。使用香港癌症登记处按年龄、性别和历年特定的癌症发病率计算标准化发病率比(SIR)。
中位随访7.5年时,共识别出51例SPT(6.7%),其中22例(43.1%)发生在既往放疗野内。舌癌(31.8%)和头颈部肉瘤(31.8%)是最常见的野内SPT。年龄[风险比(HR),1.051;95%置信区间(CI),1.025 - 至1.078]和吸烟状况(HR,1.755;95%CI,1.002 - 3.075)是与SPT发生相关的独立危险因素。SPT诊断后的中位总生存期为2.9年。与一般人群相比,癌症风险增加了84%(SIR,1.84;95%CI,1.37 - 2.42)。在肉瘤、舌癌、口咽癌、前列腺癌和肝癌中观察到显著的超额风险。随访5年后超额风险更高。
NPC根治性IMRT后存在发生SPT的重大风险,尤其是野内肉瘤和舌癌。SPT严重影响NPC幸存者的寿命。对于这种晚期致命并发症,需要高度警惕并进行仔细监测。